The prophylacticaltreatmentofrespiratoiy distress syndrome with betamethasone is used successfully inmanyclinics [2,6,19,20 J 21,27] .Adisadvantage of betamethasone administration is the regulär fall of estrogen levels in maternal urine or plasma, which may lead to difficulties in the evaluation of the fetal condition in pregnancies at risk. SIMMER et al. [24] and OHRLANDER and GENNSER [18] have studied steroidgenesis in the fetoplacental unit following corticosteroid injection. They * This work was supported by Humboldt-Foundation and Deutsche Forschungsgemeinschaft SFB 87, Project C 4 , C 5 and C 7 . ** At present Humboldt Fellow. Permanent adress: Department of Obstetrics and Gynecology, University of Cluj-Napoca, Romania. could show a decrease of total estrogens in 24-hour-urine. OHRLANDER [18] and GENNSER [8] where able to demonstrate a decrease of Cortisol in maternal and fetal plasma and amniotic fluid following betamethasone injection. ARAI [1] reported a drop of estrogens in maternal and fetal plasma after intramuscular injection of dexamethasone into the fetus in utero. TOWNSLEY [29] showed a 19% reduction of estrogen excretion in 24-hour-urine following betamethasone injection to the pregnant baboon. TOMBY RAJA [28] injected betamethasone in order to reduce estrogen levels äs a treatment to prevent premature labour. In our investigations we wanted to examine the influence of betamethasone on estrogen-biosynthesis in the piacenta and fetus. To our knowledge there is no study examining the changes of steroid hormone levels in maternal plasma in short intervals after betamethasone injection to the mother. Furthermore we wanted to know wether the changes of estrogen concentration in plasma following betamethasone administration to the mother could be of use äs a new dynamic functional test of the piacenta and the fetus. It was also planne d to test the steroidbiogenetic-function of the piacenta after betamethasone suppression-of the fetal pituitary-adrenal axis by DHA-S loading.
s l Material and methods
We used Celestan Solubile made by BYK ESSEX, l ml containing 5.3 mg. betamethasone-sodium-phosphate, representing 4 mg. betamethasone. Maternal plasma concentrations of estrone estradiol-17-beta (E 2 ), estriol (E 3 ), cortisol and total estrogens in 24-hour-urine where determined in normal and pathological third trimester pregnancies. A total of 32 volunteers was examined and subdivided into VII groups.
Group I: Threepatientswith normaluncomplicated pregnancies received 12 mg betamethasone intramuscularly on two successive days. Group II: TwopatientssufferingfromEPH-gestosis and one from placental insufficiency received 12 mg betamethasone intramuscularly on two successive days. Group III: Four patients with normal pregnancies received 8 mg betamethasone intravenously. Group IV: Three patients with normal pregnancies received 8 mg. betamethasone and an additional 25 mg DHA-S intravenously three hours later. Group V: Two patients with pathological pregnancies (placental insufficiency) received 8 mg betamethasone. Three hours later they received 25 mg DHA-S intravenously. Group VI: Four patients with normal pregnancies received 8 mg betamethasone. 50 mgDHA-Swere given intravenously 30 minutes later. Group VII: Six patients with normal and six with pathological pregnancies (placental insufficiency) received 8 mg betamethasone and an additional 50 mg DHA-S intravenously three hours later.
Collection of 24-hour-urine for determination of total estrogens was performe d the day before injection and during the six following days. Maternal venous blood for determination of E 1? E 2 , E 3 , äs well äs cortisol was drawn before injection of betamethasone and at short intervals during the first day of treatment (see figures for exact timing) and one hour after the second injection on day 2 in groups I and II. One blood sample was drawn on each of the six subsequent days at 9 a.m. The plasma was separated by centrifugation at 3000 rpm and stored frozen until used for the assay. Radioimmunoassays of EJ, E 2 and E 3 were performed with specific antibodies which were a gift from Dr. GOEBEL, München and Dr. KÜNZIG, Köln. The assay procedure was described previously [25] . Different volumes of undiluted plasma were extracted with 10 volumes of ether for determination of the unconjugated estrogen fractions. A photometric method was employed to determine the total urinary estrogens. Unconjugated cortisol was determined by the method of MURPHY [16].
Results and discussion
The basal values of E l9 E 2 , E 3 in maternal plasma were considerably higher in normal pregnancies compared to pathological pregnancies (Fig. l, 2) .
Following injection of betamethasone, plasma and urinary concentrations of estrogensdecreasebecause of diminished adrenocortical precursor availability in the fetal and maternal compartment [23, 24] .
The decrease of plasma-estrogens, cortisol and of the urinary-estrogens is dose-dependent and reaches a maximum after the second betamethasone injection. A greater percentage of the total diminuition in plasma estrogens is observed three hours after the first betamethasone injection (Fig. l ,2,4) . The investigation of plasma estrogen changes following betamethasone shows a great difference between normal and pathological pregnancies. The decrease of E 2 three hours after intramuscular injection of betamethasone was 69% of control values in normal compared to 33% in pathological cases. The drop of E 3 was also more prominent in normal pregnancies(63%) compared to complicated cases (42%), (Fig. 1,2) . In normal pregnancies it took 3 days for estrogen values to return to basal levels. In pathological pregnancies 5 days were required before basal values were attained. Thus pathological cases seem to reach preinjection control estrogen values later than normal pregnancies. Plasma E 3 concentrations need the longest time to return to basal values. This could be caused by a longer suppression of the fetal than of the maternal pituitary-adrenal axis [24] , Betamethasone may produce suppression of 16X-hydroxlase in the fetal liver without influencing the placental aromatisation. In one case of EPH-gestosis and intrauterine fetal death, concentrations of E l5 E 2 , and E 3 showed little change following betamethasone in contrast to normal control cases. A more pronounced after the second betamethasone application. It is to be stressed however that the cortisol levels in our patients were mostly within normal limits. The concentrations of DHA in maternal plasma and urine show only a small change following betamethasone application in normal and pathological pregnancies [17] .
Since the suppression of the maternal adrenal cortex following betamethasone is about the same in normal and pathological pregnancies, one could draw the conclusion that differences in estrogen decreases are mostly due to the difference in suppression of estrogen precursor-biosynthesis between the normal fetus and the fetus at risk.
Changes of plasma estrogens following betamethasone application correspond well with changes of urinary estrogens (Fig. 3) . The maximal mean decrease of urinary estrogens was 76% in normal pregnancies. It was reached the first day after the second betamethasone application. At the same time the maximal drop for the lower control values of pathological pregnancies was only 50% of basal values. The return to basal values was not reached within four days after the second betamethasone injection in both groups.
It has been reported, that the return to basal values is reached in 2-3 weeks [5, 20] or after 5-6 days 421,22]. Maternal plasma concentrations of estrone (Ed id not show specific changes during the first days following betamethasone injection. According to the results from the patients of group IV, V and VI plasma E 2 and E 3 show more pronounced decreases in normal pregnancies than in pathological pregnancies. The E 2 and E 3 increase occurring 30 minutes after DHA-S injection is also higher in normal pregnancies (Fig. 5,6 ). Intravenous injection of 50 mg DHA-S immediately after intravenous betamethasone injection causes a smaller increase of plasma E 3 (since the suppression of the fetal pituitary-adrenal axis is still minimal at this time) than a smaller ; dose of DHA-S (25 mg) administered three hours later (Fig. 7) .
A hypothetical explanation is that endogenous estrogen precursors and exogenous DHA-S compete for aromatisation in the placent [10, 13, 30] . The increase of plasma E 3 (89%) following DHA-S injection in patients of group IV is quite similar to that in the cases examined by STRECKER and LAURITZEN [25] . BUSTER [3] did not find an increase of plasma E 3 following DHA-S injection. The increase of E 3 after betamethasone Inhibition could be explained by an activation of the "phenolic pathway" (16-alfa-hydroxylation in the maternal liver) [7,22j. The different patterns of plasma concentrations for £2, E 3 and urinary estrogens following betamethasone and DHA-S injection in normal and pathological pregnancies encouraged us to apply this idea to a new modified dynamic test of fetoplacental function: "A betamethasone suppression-PHA-S Stimulation Test". We think that this test will give us more and new Information about fetal and placental compartments in normal and pathological pregnancies.
The influence of betamethasone on the fetoplacental unit is demonstrated in Fig. 8 . 
Basal theoretical knowledge concerning the test
Investigations of ophorectomized patients have show that there is a minimal basal DHA secretion of the adrenal cortex even after complete suppression of ACTH. Also, it is well known that there is no gonadal DHA production in the fetus. OHRLANDER [18] could show there is minimal estriol excretion in maternal urine (aproximately 2 mg) even after complete suppression of ACTH. These results show the existence of a basal adrenal cortex secretion of estrogen precursors which is independent of hypothalamic-pituitary Stimulation. One could say that after suppression of the pituitary-adrenal cortex axis by betamethasone, the determination of plasma estrogens gives Information about the basal adrenal secretion of estrogen precursors and the extent of adrenal cortical suppression. CHALLIS [4] has examined plasma concentrations of androstenedione, testosterone, estrogens and cortisol after betamethasone application to rhesus monkeys. He found a more pronounced suppression of estrogens than androgens. The androgens remained at a constant level after an initial drop. The decrease of estrogens was continual, indicating that it was caused by a suppression of the fetal adrenal cortex.
SIMMER demonstrated [23, 24] that the decrease of €χ9 estrogen precursors following corticosteroid application was more intense in the umbilical vein than in maternal plasma. We believe that the dynamic determination of maternal plasma estrogens after betamethasone application represents a test for the suppression of the pituitary-adrenal cortex axis.
The following reasons are listed in support of this contention:
1. The extent of the plasma estrogen decrease following betamethasone application shows predominantiy the fetal portion of the pool of estrogen-precursors. Maternal precursors show little change.
2.
The basal estrogen level that remains constant over a period of time after betamethasone suppression shows preponderately the maternal portion of the pool of estrogen precursors. 3. The extent of the estrogen-fall represents a measure of the fetal pituitary-adrenal suppression and of the ability of the adrenal cortex to respond to factors acting on the feed back mechanisms. This may be important for the adaptation to situations of stress in utero.
4. After maximal suppression of the fetal estrogen precursors, conditions of an "in vivo" isolation of the placenta are created.
In this way it should be possible to evaluate separately e.g. the aromatisation rate of the placenta after DHA-S loading without interference from the fetal or maternal side.
The response of the adrenal cortex to pituitary ACTH depends on the intensity and duration of this Stimulation. The adrenal cortex of a normal fetus reacts with an imme diäte and adequate secretion of corticosteroids. ISHERWOOD and OAKEY [9] could demonstrate an increased production of androgens "in vitro" following ACTHstimulation. Direct injection of ACTH and HCG into the fetus showed significant rises of maternal estrogens via an increase of fetal estrogen precursors [1, 12, 26] .
Animal investigations have shown an increased secretion of ACTH in fetus suffering from chronic or acute hypoxia. There was no rise of plasmacortisol levels found in fetuses with chronic hypoxia [31] . The estrogen response pattern following betamethasone application changes with the condition of the fetus. A healthy, normal fetus reacts with a more intense decrease of estrogens than a fetus at risk, and the retum to values before injection is more rapid.
In normal pregnancies the decline of E 3 three hours after intravenous injection of 8 mg betamethasone exceeds 50% of preinjection values. This decrease showed good correlations to clinical Undings, erg. the cardiotocogram and human placental lactogen (HPL). HPL levels are not influenced by corticosteroid application to themother [19, 20, 32] .OHRLANDE R [18] could show a direct correlation between basal estriol-excretion in the 24-h-urine and its decrease after betamethasone injection. In pathological pregnancies the decline of the primarily low estrogen levels is less distinct and the return to basal values is slower.
The most important criteria for the Interpretation of the estrogen curves following betamethasone suppression seem tobe the extension of the plateau together with the amplitude of the curve and the time required for preinjection control values to be reached.
With an additional application of 50 mg DHA-S three hours after betamethasone injection to the mother and determination of maternal plasma estrogens in short intervals there might be the possibility of a new more sophisticated functional method of determining placental function: "An Inhibition test of the fetal pituitary-adrenal cortex axis combined with a loading-test of the placenta."
This test could evaluate the condition of the fetus by determination of E 3 after betamethasone application to the mother and could also clarify the reserve capacity of the placenta following DHA-S loading, in a state of maximal suppression of the endogenous estrogen-precursors by determination of E 2 ( Fig. 9 ).
There are numerous reports about the theory and the clinical value of the DHA-S loading-test in plasma [10, 11, 13, 14, 15, 25, 30] .
The criteria of normality for this part of the combined test mentioned above agree with those. reported by STRECKER and LAURITZEN [25] .
In this way an improvement of the DHA-S loading test may be possible since the fetal and to a smaller extent the maternal estrogen precursors are excluded.
The following conclusions can be drawn from our investigations l.The changes of plasma and urinary estrogen levels depend on the dose of betamethasone and on the way of application. 2. The maximal decrease of maternal E 2 and E 3 is reached three hours after injection. The return to preinjection values takes more than 4-5 days.
3. The decline of estrogens following betamethasone injection to the mother is caused by suppression of adrenocortical estrogen-precursors mainly derived from the fetus. 4. The changes of maternal plasma estrogens after betamethasone and subsequent DHA-S loading offer new possibilities for testingthe fetoplacental unit.
Plasma £3 ng/ml Plasma £2 ng/ml Betamethasone suppression -r DHA-S-loading-test A total of 32 patients was examined und subdivided into VII groups.Group 1,11 andlllreceived 12 mg betamethasone im. or 8 mg iv. Group IV, V,VI, VII received betamethasone and also 25 or 50 mg DHA-S iv.
Maternal venous blood for determination of Ej, E 2 and E 3 äs well äs cortisol was drawn before injection of betamethasone and at short intervals during the first day of treatment (see figures for exact timing) and one hour after the second injection on day II in the cases of group I and II. One blood sample was drawn on each of the six subsequent day s at 9 a.m. E!, E 2 and E 3 were determined by radioimmunoassay. A photometric method was employed to determine the total urinary estrogens. Unconjugated cortisol was determined by the method of MURPHY.
The basal values of E 1? E 2 , E 3 in mafernal plasma where considerably higher in normal pregnancies than in pathological pregnancies (Fig. l, 2, 3, 4) .
The decrease of plasma-estrogens, cortisol and of the urinary-estrogens is dose dependent and reaches a mäxi-mum on the second betamethasone injection (Fig. l, 2, 3 ).
Plasma estrogen changes following betamethasone show a great difference between normal and pathological pregnancies. The decrease of E 2 three hours after intramuscular injection of betamethasone was 69% in normal compaied to 33% in pathological cases. The drop of E 3 was also more prominent in normal pregnancies (63%) than in complicated cases (42%) ( Fig. l  and 2) . Estrogen values of normal pregnancies returned to basal values three days after injection. In pathological pregnancies 5 days elapsed before values were normal again.
In patients of group IV, V and VI the increases of plasma E 2 and E 3 occurring 30 minutes after DHA^S injection are also higher in normal that in pathological pregnancies (Fig. 5, 6 ). The different patterns of plasma concentrations of E 2 , E 3 and urinary estrogens following betamethasone and DHA-S injection in normal and pathological pregnancies encouraged us to apply this idea to a.new modified dynamic test of feto-placental function: "AJbetamethasone suppression DHA-S-loading Test". The estrogen response pattern following betamethasone application changes with the condition of the fetus. A healthy, normal fetus reacts with a more intense decrease of estrogens than a fetus at risk and the return to values before injection is more rapid.
In cases of a "normal response" the decline of E 3 three hours after intravenous injection of 8 mg betamethasone exceeds 50% of preinjection values. In pathological pregnancies the decline of the primarily low estiogen levels is less distinct and the return to basal values is slower.
With an additional application of 50 mg DHA-S three hours after betamethasone injection to the mother and determination of maternal plasma estrogens in short intervals there might be the possibility of a new functional method determining placental function: "An Inhibition test of the fetal pituitary-adrenal axis combined with a loading-test of the placenta.". This test could evaluate the condition of the fetus by determination of £3 after betamethasone application to the mother and could also clarify the reserve capacity of the placenta following DHA-S loading in a state of maximal suppression of the endogenous estrogen-precursors by determination of E 2 (Fig. 9) .
The following conclusions can be drawn from our investigations:
1. The changes of plasma and urinary estrogens depend on the dose of betamethasone and on the way of application. 2. The maximal decrease of maternal E 2 and £3 is reached three hours after injection. The return to preinjection values takes more than 4-5 days. 3. The decline of estrogens following betamethasone injection to the mother is causes by suppression of adrenocortical estrogen-precursors mainly derived from the fetus. 4. The changes of maternal plasma estrogens after betamethasone and subsequent DHA-S loading offer new possibilities for testing the fetoplacental unit. fig. l, 2, 3,4) . La baisse des oestrogenes plasmatiques, du cortisol et des oestrogenes urinaires depend de la (lose et atteint un maximum apres la.seconde injection de betamethasone ( fig. l, 2, 3) . Les investigations des changements des oestrogenes plasmatiques apres betamethasone montrent une grande difference entre les grossesses normales et pathologiques. La baisse d'OE^ trois heures apres l'injection intramusculaire de betamethasone a atteint 69% dans les grossesses normales et seulement 33% dans les grossesses pathologiques' La baisse dOE 3 a ete egalement plus importante dans les cas normaux (63%) que dans les cas compliques (42%) ( fig. l et 2) . Les valeurs des oestrogenes en grossesse normale ont retrouve leur niveau de depart trois jours seulement apres l'injection et meme 5 jours pour les grpsses pathologiques. Selon les resultats des patientes des groupes IV, V et VI, les hausses dOE 2 et dOE 3 plasmiques 30 minutes apres l'injection de DHA-S sont plus grandes en grossesse normale qu'en grossesse pathologique. (fig. 5 et 6) . La difference des courbes des concentrations plasmiques d'OE 2 , d'OE 3 et des oestrogenes urinaires apres l'injection de betamethasone et de DHA-S entre les grossesses normales et pathologiques nous a incites a"appliquer cette idee comme un nouveau test dynamique de la fonction foetoplacentaiie: «Un test d'inhibition par betamethasone et de Stimulation par DHA-S». La reaction des oestrogenes apres l'injection de betamethasone varie selon la condition du foetus. Un foetus normal et sain reagit par une baisse plus forte des oestrogenes qu'un foetus «a risque» et le retour aux valeurs de base (c.a.d. precedant l'injection) est plus rapide. Dans les cas d'une «reaction normale», la baisse d'OE 3 trois heures apres l'injection intraveineuse de 8 mg de betamethasone depasse 50% des valeurs initiales. Dans les cas des grossesses pathologiques la baisse des valeurs initialement basses des oestrogenes est moins prononcee et le retour aux valeurs de base est plus lent. L'injection supplementaire de 50 mg de DHA-S trois heures apres l'injection de betamethasone a la mere et la determination des oestrogenes plasmatiques maternels a courts intervalles pourrait nous donner la possibilite d'appliquer une nouvelle methode pour definir la fonction placentaire: «Un test d'inhibition de Taxe hypophisoadrenocortical combine avec un loading-test» du placenta.
Ce test pourrait permettre d'evaluer la condition du foetus en determinant 1OE 3 apres l'injection de betamethasone ä la mere ainsi que la capacite de reserve placentaiie apres Padministration de DHA-S au moment de la suppression maximale des precurseurs endogenes des oestrogenes par determination dOE 2 (fig. 9 ). Les resultats obtenus nous ont permis de tirer les conclusions suivantes:
